Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 2, 2026, 7:14 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 73–96 of 543 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Standard of Care Dosing Clear all
Recruiting Not applicable Interventional

Prescription Antipyretics to Decrease Unscheduled Return Visits In A Pediatric Emergency Department

NCT07074912
View directory record Official record
Conditions
Fever
Interventions
Prescription for weight-based dosing of antipyretic, Standard discharge instructions
Other
Lead sponsor
University of Texas at Austin
Other
Eligibility
6 Months to 36 Months
Enrollment
440 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Jul 20, 2025 · Synced Oct 2, 2026, 7:14 AM EDT
Recruiting Phase 2 Interventional Accepts healthy volunteers

Pharmacogenomics for Better Treatment of Fungal Infections Clinical Trial

NCT06510699
View directory record Official record
Conditions
Fungal Infection, Haematological Malignancy, Blood Cancer, Infectious Disease
Interventions
genotype-directed dosing with dosing software based on therapeutic drug monitoring
Other
Lead sponsor
The University of Queensland
Other
Eligibility
2 Years and older
Enrollment
104 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2027
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Apr 16, 2026 · Synced Oct 2, 2026, 7:14 AM EDT
Recruiting Phase 1 Interventional

DSP-0390 in Combination With Atezolizumab for Small Cell Lung Cancer

NCT07545954
View directory record Official record
Conditions
Small-cell Lung Cancer, Small Cell Lung Cancer Extensive Stage
Interventions
DSP-0390, Atezolizumab
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Aug 4, 2026 · Synced Oct 2, 2026, 7:14 AM EDT
Completed Phase 2 Interventional Results available

Phase 2 Pilot Trial of Subjects With Complex Non-healing Diabetic Foot Ulcers Treated With Standard Care Plus Cryopreserved Umbilical Cord Allograft (TTAX01)

NCT03230175
View directory record Official record
Conditions
Non-healing Wound, Non-healing Diabetic Foot Ulcer, Diabetic Foot Infection
Interventions
TTAX01, Surgical resection and debridement, Systemic antibiotics, Off-loading
Biological · Procedure · Drug + 1 more
Lead sponsor
BioTissue Holdings, Inc
Industry
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
11
States / cities
Phoenix, Arizona • Sylmar, California • Miami, Florida + 8 more
Source: ClinicalTrials.gov public record
Updated Jun 15, 2021 · Synced Oct 2, 2026, 7:14 AM EDT
Completed Phase 3 Interventional Results available

First-line Esophageal Carcinoma Study With Pembrolizumab Plus Chemo vs. Chemo (MK-3475-590/KEYNOTE-590)

NCT03189719
View directory record Official record
Conditions
Esophageal Neoplasms
Interventions
Pembrolizumab, Placebo, Cisplatin, 5-FU
Biological · Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older
Enrollment
749 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2023
U.S. locations
12
States / cities
West Los Angeles, California • Chicago, Illinois • Westwood, Kansas + 9 more
Source: ClinicalTrials.gov public record
Updated Oct 15, 2024 · Synced Oct 2, 2026, 7:14 AM EDT
Not yet recruiting Not applicable Interventional

MH-Rx Study (Baby on Board: Check-in on You, Your Medication, & Your Blood Pressure)

NCT07842341
View directory record Official record
Conditions
Hypertensive Disorders of Pregnancy, Chronic Hypertension in Pregnancy, Gestational Hypertension
Interventions
Community Health Worker (CHW)/Social Worker (SW)-led non-medical health related needs (NMHRN) intervention + Clinician-Led Medication Therapy Management (MTM) with remote blood pressure monitoring, Active Comparator (Control group)
Behavioral
Lead sponsor
Texas Southern University
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
158 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 25, 2026 · Synced Oct 2, 2026, 7:14 AM EDT
Terminated No phase listed Observational

Impact of Pre-surgical Nasal Bacterial Reduction on Postoperative Surgical Site Infections / Standard Care Change

NCT01148030
View directory record Official record
Conditions
Surgical Site Infection
Interventions
3M Skin and Nasal Antiseptic
Drug
Lead sponsor
3M
Industry
Eligibility
2 Years and older
Enrollment
333 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Mar 3, 2014 · Synced Oct 2, 2026, 7:14 AM EDT
Not listed Phase 2 Interventional

Early Conversion From CNI to Belatacept in Renal Transplant Recipients With Delayed and Slow Graft Function

NCT01837043
View directory record Official record
Conditions
Delayed Graft Function, Kidney Transplant
Interventions
Belatacept, Calcineurin Inhibitor
Drug
Lead sponsor
Nair, Vinay, D.O.
Individual
Eligibility
18 Years to 70 Years
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 30, 2017 · Synced Oct 2, 2026, 7:14 AM EDT
Completed Not applicable Interventional Results available

Virtual Reality as a Substitute for Procedural Sedation During Epidural Steroid Injections

NCT04887285
View directory record Official record
Conditions
Lower Back Pain, Lumbar Radiculopathy
Interventions
Virtual reality, Intravenous sedation, Standard care
Device · Drug · Other
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 90 Years
Enrollment
146 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 2, 2024 · Synced Oct 2, 2026, 7:14 AM EDT
Completed Phase 4 Interventional Results available

Fixed Versus Variable Dosing of 4-factor Prothrombin Complex Concentrate for Emergent Warfarin Reversal

NCT03064035
View directory record Official record
Conditions
Acute Bleeding on Long-Term Anticoagulation Therapy, Hemorrhage, Significant Bleeding in Patients With a Coagulopathy (Prolonged Thrombin Time), Urgent Reversal of Vitamin K Antagonist (VKA) Anticoagulation
Interventions
4-factor prothrombin complex concentrate (4FPCC)
Drug
Lead sponsor
HealthPartners Institute
Other
Eligibility
18 Years to 125 Years
Enrollment
79 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Saint Paul, Minnesota
Source: ClinicalTrials.gov public record
Updated Sep 14, 2023 · Synced Oct 2, 2026, 7:14 AM EDT
Recruiting Phase 2 Interventional

A Study of Melphalan With or Without Siltuximab in People With Multiple Myeloma Having an Autologous Stem Cell Transplant

NCT06679829
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Siltuximab, Melphalan
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
60 Years and older
Enrollment
215 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
7
States / cities
Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more
Source: ClinicalTrials.gov public record
Updated Oct 1, 2026 · Synced Oct 2, 2026, 7:14 AM EDT
Completed Not applicable Interventional Results available

A Trial To Assess Risk of Delirium in Older Adults Undergoing Hip Fracture Surgery With Spinal or General Anesthesia

NCT02190903
View directory record Official record
Conditions
Postoperative Complications, Hip Fracture, Delirium
Interventions
General endotracheal anesthesia, Regional (spinal) Anesthesia
Other
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 30, 2018 · Synced Oct 2, 2026, 7:14 AM EDT
Terminated Phase 2 Interventional

Pharmacodynamic Study of CK-2017357 in Patients With Generalized Myasthenia Gravis

NCT01268280
View directory record Official record
Conditions
Myasthenia Gravis
Interventions
Placebo, 250 mg CK-2017357, 500 mg CK-2017357
Drug
Lead sponsor
Cytokinetics
Industry
Eligibility
18 Years to 80 Years
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
15
States / cities
Fresno, California • Orange, California • San Francisco, California + 12 more
Source: ClinicalTrials.gov public record
Updated Sep 24, 2019 · Synced Oct 2, 2026, 7:14 AM EDT
Recruiting Phase 4 Interventional

Continuous vs Intermittent Ketorolac for Pain Control in Peds CV Surgery

NCT04040452
View directory record Official record
Conditions
Congenital Heart Disease in Children
Interventions
Continuous ketorolac
Drug
Lead sponsor
Phoenix Children's Hospital
Other
Eligibility
3 Months to 59 Months
Enrollment
166 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
1
States / cities
Phoenix, Arizona
Source: ClinicalTrials.gov public record
Updated Aug 12, 2026 · Synced Oct 2, 2026, 7:14 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Efficacy and Safety Study of Fibrin Sealant With 4 IU/mL Thrombin, Vapor Heated, Solvent Detergent Treated (FS VH S/D 4) in Face-Lift Procedures

NCT00708071
View directory record Official record
Conditions
Facial Rhytidectomy (Face-lift)
Interventions
Fibrin Sealant with 4 IU/ml Thrombin, Vapor-Heated, Solvent Detergent Treated Containing Synthetic Aprotinin (FS VH S/D 4)
Biological
Lead sponsor
Baxter Healthcare Corporation
Industry
Eligibility
18 Years to 75 Years
Enrollment
45 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008
U.S. locations
6
States / cities
Beverly Hills, California • Los Angeles, California • Atlanta, Georgia + 3 more
Source: ClinicalTrials.gov public record
Updated Oct 23, 2012 · Synced Oct 2, 2026, 7:14 AM EDT
Withdrawn Not applicable Interventional Accepts healthy volunteers

Effects of Remote Motivational Enhancement & MySafeRx on Post-Detox Engagement in B/N Treatment -RCT

NCT04822168
View directory record Official record
Conditions
Opioid-use Disorder
Interventions
MySafeRx™, Standard Care
Other
Lead sponsor
University of South Florida
Other
Eligibility
18 Years to 65 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Dec 7, 2021 · Synced Oct 2, 2026, 7:14 AM EDT
Completed Phase 1 Interventional

A Study to Evaluate Subcutaneous TAK-079 Added to Standard of Care Regimens in Participants With Newly Diagnosed Multiple Myeloma (NDMM)

NCT03984097
View directory record Official record
Conditions
Multiple Myeloma
Interventions
TAK-079, Lenalidomide, Dexamethasone, Bortezomib, Pomalidomide
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
9
States / cities
Birmingham, Alabama • Monterey, California • Bethesda, Maryland + 6 more
Source: ClinicalTrials.gov public record
Updated Apr 9, 2026 · Synced Oct 2, 2026, 7:14 AM EDT
Withdrawn Phase 4 Interventional

Belatacept in Kidney Transplantation of Moderately Sensitized Patients

NCT02130817
View directory record Official record
Conditions
End Stage Renal Disease, Antibody Mediated Rejection
Interventions
Belatacept, Tacrolimus withdrawal, Plasmapheresis/Intravenous Immunoglobulin G, Thymoglobulin (ATG), Myfortic, Steroids
Drug · Procedure
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years to 70 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Dec 17, 2018 · Synced Oct 2, 2026, 7:14 AM EDT
Recruiting Early Phase 1 Interventional

Study of Letrozole in Recurrent Gliomas

NCT03122197
View directory record Official record
Conditions
Brain Tumor
Interventions
Letrozole Oral Tablet, Temozolomide
Drug
Lead sponsor
University of Cincinnati
Other
Eligibility
18 Years and older
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2027
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Aug 18, 2026 · Synced Oct 2, 2026, 7:14 AM EDT
Active, not recruiting Phase 3 Interventional

Study to Compare Axicabtagene Ciloleucel With Standard of Care Therapy as First-line Treatment in Participants With High-risk Large B-cell Lymphoma

NCT05605899
View directory record Official record
Conditions
High-risk Large B-cell Lymphoma (LBCL)
Interventions
Axicabtagene Ciloleucel, Cyclophosphamide, Fludarabine, Etoposide, Rituximab, Doxorubicin, Vincristine, Prednisone
Biological · Drug
Lead sponsor
Kite, A Gilead Company
Industry
Eligibility
18 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2031
U.S. locations
32
States / cities
Birmingham, Alabama • Gilbert, Arizona • Phoenix, Arizona + 26 more
Source: ClinicalTrials.gov public record
Updated Apr 15, 2026 · Synced Oct 2, 2026, 7:14 AM EDT
Completed Phase 4 Interventional Results available

Hospital Insulin Protocol Aims for Glucose Control in Corticosteroid-induced Hyperglycemia

NCT01184014
View directory record Official record
Conditions
Hyperglycemia
Interventions
NPH insulin plus Complete Insulin Orders, Complete Insulin Orders
Drug
Lead sponsor
HealthPartners Institute
Other
Eligibility
18 Years and older
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
Saint Louis Park, Minnesota
Source: ClinicalTrials.gov public record
Updated Jun 13, 2018 · Synced Oct 2, 2026, 7:14 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Vancomycin Dose Optimization in Obesity

NCT06601257
View directory record Official record
Conditions
Pharmacokinetics and Pharmacodynamics
Interventions
Vancomycin (IV)
Drug
Lead sponsor
University of Michigan
Other
Eligibility
18 Years to 50 Years
Enrollment
35 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated May 22, 2026 · Synced Oct 2, 2026, 7:14 AM EDT
Recruiting Phase 2 Interventional

Trial of 2 Step ATG for Acute GVHD Prevention Post Myeloablative Allogeneic Stem Cell Transplant

NCT06315309
View directory record Official record
Conditions
GVHD,Acute, Acute Leukemia, Myelodysplastic Syndromes, Myeloproliferative Disorders
Interventions
ATG Combined with Tacrolimus and Mini Methotrexate
Drug
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
18 Years to 60 Years
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Oct 8, 2025 · Synced Oct 2, 2026, 7:14 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

Weight-Based Torsemide Dosing in Subjects With Heart Failure

NCT03187509
View directory record Official record
Conditions
Heart Failure
Interventions
Torsemide, Standard Outpatient Heart Failure Management
Drug · Other
Lead sponsor
New York City Health and Hospitals Corporation
Other
Eligibility
18 Years to 90 Years
Enrollment
52 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2022
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Mar 15, 2022 · Synced Oct 2, 2026, 7:14 AM EDT